PhytoMedical Technologies, Inc. today announced that research and development of the Company's proprietary BDC-03 compound has been expanded to include investigations of High Density Lipoproteins (HDL), shown in a study to be favorably elevated by BDC-03. The results of an initial animal study showed that BDC-03 has pharmacologically active elements that have the potential to reduce body fat percentage, lower cholesterol, and most importantly, increase lean muscle.
Business Wire